S. 1214 · 118th Congress (2023–2025)
RARE Act
This bill specifies that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drug exclusivity period) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition.
Current law grants a seven-year period of market exclusivity for an approved orphan drug, during which the Food and Drug Administration (FDA) may not approve an application from another manufacturer for the same drug for the same disease or condition. The FDA's regulations provide that this exclusivity is specific to the same approved use or indication of the drug, rather than all uses or indications, for the disease or condition. However, in Catalyst Pharmaceuticals, Inc. v. Becerra, a court held that exclusivity did extend to all uses or indications for the disease or condition.
The bill provides statutory authority for the FDA's regulations.
Show official title
A bill to set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReported by committee
This bill’s path
This is S. 1214’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Tammy Baldwin (D-WI)
- Cosponsors
1 cosponsor
0 original · 1 later
- Sen. Mike Braun (R-IN)· Later · Apr 26, 2023
- Policy area
- Health
- Subjects
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Licensing and registrations
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Apr 19, 2023 – Jun 22, 2023
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders without amendment. Without written report.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Reported by committee → No further action before the 118th Congress ended.
Committees
- SenateHealth, Education, Labor, and PensionsReferred Apr 19, 2023 · Markup May 11, 2023 · Reported Jun 22, 2023
May 11, 2023 · Meeting
May 2, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (3)
RARE Act
Display title, Short title · Introduced in Senate, Reported to Senate
Retaining Access and Restoring Exclusivity Act
Short title · Introduced in Senate, Reported to Senate
A bill to set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions.
Official title · Introduced in Senate